A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Steve Christo – Corbis/Getty Images Semaglutide is a GLP-1 agonist medication that can assist with diabetes management and weight loss ... Participants received 2.4mg injections of semaglutide ...